Fig. 1: Evaluation of baseline immune-status by immunohistochemistry and diagnosis characteristics in patient-derived ovarian cancer samples.

Upon arrival, fragments of ovarian cancer samples were fixed and embedded into paraffin blocks, and staining with HE and immunohistochemistry for CD4+ T, CD8+ T, CD56+, and PD-L1+ cells were performed. A–C Chart graphs detailing ovarian cancer characteristics on (A) diagnosis, (B) location of resected specimen, and (C) prior cancer therapies. D Expression of PD-L1 percentages levels on cancer cells, immune cells and overall counting in ovarian cancer samples. E Ratio of CD4+/CD8+ T cell infiltration across study samples. F Baseline maximum counting of CD4+ T cell infiltration across all ovarian cancer tumors in ×400 power field. G Baseline maximum counting of CD8+ T cell infiltration across all ovarian cancer tumors in ×400 power field. H Baseline relative counting of CD56+ infiltrating lymphocyte present in each ovarian cancer samples. I Photos of slides representing lymphocyte infiltration in an ovarian cancer samples. From left to right, HE staining showing in yellow cancer cells (CC) and immune cells (IC) grouping, CD4+ T cells (brown), CD8+ T cells (brown), and CD56+ cells (red arrows) distribution in the same tumor area. IHC photos from HUSOV16 slides were used to exemplify the lymphocyte infiltration pattern. Upper row ×26 magnification (scale bar 200 µm) and lower row ×33 magnification (scale bar 100 µm). Partial data was published as Quixabeira et al, 2022 at ESMO Immuno-Oncology 2022.